China grants country's first COVID-19 vaccine patent to CanSino, says media report

Chinese state media reported that the patent was issued on August 11.

August 17, 2020 09:44 am | Updated 10:00 am IST - BEIJING

CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, according to state media. (Representative image)

CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, according to state media. (Representative image)

China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.

The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on August 11.

Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.

CanSino's Hong Kong shares rose around 14% in Monday's morning session. Its Shanghai shares rose by 6.6% as of midday.

Top News Today

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.